Research Grade Ocaratuzumab(TD-HY257126) is ahumanized monoclonalantibody detectingB-lymphocyte surface antigen B1inELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable forHuman.HighlightsMulti-Application— Validated across multiple applications.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Humanized
Isotype
IgG1-kappa
Species
Human
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names
AME-133v, LY2469298, 1169956-08-4
Background
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.
Caption
Detects Human CD20/MS4A1 in indirect ELISAs. | SDS-PAGE for Research Grade Ocaratuzumab
Note
For research use only. Not suitable for clinical or therapeutic use.